Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

MT Newswires Live

Sep 24

Eupraxia Pharmaceuticals (EPRX) said Wednesday that it has closed its public offering of about 14.6 million common shares priced at $5.50 per share, with the underwriters fully exercising an option to buy additional shares.

The company said it raised about $80.5 million in gross proceeds. Net proceeds will be used for further development of its product pipeline, research and development of additional pipeline candidates, business development activities, and general corporate purposes, the company added.

Shares of Eupraxia Pharmaceuticals were up more than 12% in recent Wednesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569702683"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569702683\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569702683?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569702683","market":"nz","top_or_hot":-1,"title":"Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/EPRX\">Eupraxia Pharmaceuticals</a> (EPRX) said Wednesday that it has closed its public offering of about 14.6 million common shares priced at $5.50 per share, with the underwriters fully exercising an option to buy additional shares.</p><p>The company said it raised about $80.5 million in gross proceeds. Net proceeds will be used for further development of its product pipeline, research and development of additional pipeline candidates, business development activities, and general corporate purposes, the company added.</p><p>Shares of Eupraxia Pharmaceuticals were up more than 12% in recent Wednesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEupraxia Pharmaceuticals Closes $80.5 Million Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-24 21:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/EPRX\">Eupraxia Pharmaceuticals</a> (EPRX) said Wednesday that it has closed its public offering of about 14.6 million common shares priced at $5.50 per share, with the underwriters fully exercising an option to buy additional shares.</p><p>The company said it raised about $80.5 million in gross proceeds. Net proceeds will be used for further development of its product pipeline, research and development of additional pipeline candidates, business development activities, and general corporate purposes, the company added.</p><p>Shares of Eupraxia Pharmaceuticals were up more than 12% in recent Wednesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPRX","symbol_name":"Eupraxia Pharmaceuticals","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2569702683","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569702683","pubTimestamp":1758720297,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eupraxia Pharmaceuticals  said Wednesday that it has closed its public offering of about 14.6 million common shares priced at $5.50 per share, with the underwriters fully exercising an option to buy additional shares.The company said it raised about $80.5 million in gross proceeds. Net proceeds will be used for further development of its product pipeline, research and development of additional pipeline candidates, business development activities, and general corporate purposes, the company added.Shares of Eupraxia Pharmaceuticals were up more than 12% in recent Wednesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPRX":"Eupraxia Pharmaceuticals","BK4139":"生物科技"},"translate_title":"Eupraxia Pharmaceuticals完成8050万美元公开募股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPRX":1.5},"content_text":"Eupraxia Pharmaceuticals (EPRX) said Wednesday that it has closed its public offering of about 14.6 million common shares priced at $5.50 per share, with the underwriters fully exercising an option to buy additional shares.The company said it raised about $80.5 million in gross proceeds. Net proceeds will be used for further development of its product pipeline, research and development of additional pipeline candidates, business development activities, and general corporate purposes, the company added.Shares of Eupraxia Pharmaceuticals were up more than 12% in recent Wednesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}